Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 2
R&D Momentum
55/100
Pipeline Velocity
25/100
Trial Completion Rate
88/100
Pipeline Concentration
33/100
Pipeline Freshness
20/100
Strategic Signals
Activity
Last 14 days
STOpping PPI Therapy in Inactive IBD Study (STOP-IT): A Feasibility Study
NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study
Accessing the Clarity and Acceptability of Recruitment Materials for a Study on Thoracic Aortic Disease Surveillance: A Qualitative Feasibility Study.
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)